Brain perfusion effects of cholinesterase inhibitors in Parkinson’s disease with dementia
- 14 June 2006
- journal article
- clinical trial
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 113 (11) , 1787-1790
Abstract
Several evidences suggest that cholinergic deficits may significantly contribute to dementia in Parkinson’s disease (PDD) and acetylcholinesterase inhibitors (ChEIs) have been reported to improve cognitive symptoms in PDD, without worsening parkinsonism. Nineteen PDD patients underwent brain perfusion SPECT with 99mTc-ethyl cysteinate dimer after 6 months ChEIs treatment in order to evaluate the functional correlates of clinical improvement. A clear-cut cognitive improvement was reported in PDD patients with a significant improvement of ADAS-cog total score as well as of subscores exploring executive functions (p < 0.01). MMSE total score did not significantly change after ChEIs but the subscore of attention significantly improved after therapy (p < 0.01). No difference in motor performance as evaluated by UPDRS was reported. SPM analysis showed a significant increase of perfusion (p < 0.0001) in bilateral cingulate, and frontal regions after ChEIs. Our data confirm the efficacy of ChEIs in the treatment of dementia associated with PD mainly on attention and executive functions, and the functional findings indicate that this cognitive improvement could be associated with a sort of pharmacological frontal “re-afferentation”.Keywords
This publication has 26 references indexed in Scilit:
- Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover studyJournal of Neurology, Neurosurgery & Psychiatry, 2005
- Efficacy and Safety of Donepezil in the Treatment of Executive Dysfunction in Parkinson DiseaseClinical Neuropharmacology, 2005
- Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's diseaseInternational Journal of Geriatric Psychiatry, 2004
- Clinical predictors of response to acetyl cholinesterase inhibitors: experience from routine clinical use in NewcastleInternational Journal of Geriatric Psychiatry, 2003
- Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementiaInternational Journal of Geriatric Psychiatry, 2003
- Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugsAnnals of Neurology, 2003
- Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled studyJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Working memory functioning in medicated Parkinson's disease patients and the effect of withdrawal of dopaminergic medication.Neuropsychology, 2000
- Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.Journal of Neurology, Neurosurgery & Psychiatry, 1992
- Parkinson's disease: Neuron loss in the nucleus basalis without concomitant Alzheimer's diseaseAnnals of Neurology, 1984